Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2006

View Archived Issues

Neuroprotective effects of a component of the perineuronal net

Intravail increases intranasal bioavailability in first clinical study

ConjuChem places DAC:GRF program in HIV lipodystrophy on clinical hold

Memory achieves preclinical milestones in Roche collaboration

Lpath first to generate functional antibodies against LPA

Fast track designation for intravenous methylnaltrexone in postoperative ileus

BioProgress completes acquisition of Segix Farma

BioLineRx inlicenses orally available peptide for treatment of obesity

Positive results for PT-502 in animal model for antidepressant activity

Enzo cleared for phase II study of EGS-21 in NASH

Crucell suspends further development of Aerugen

Enrollment under way in phase I study of INNO-406 in leukemias

BioDelivery Sciences submits Emezine study plans to FDA

TH-070 fails to meet endpoint in BPH phase II and phase III trials

Cimzia shows potential in psoriasis

GM-CSF enhances immune response to melanoma vaccine Vaccimel

Analyses point to mycophenolate mofetil efficacy in lupus nephritis

CNRS present new data on BACE1 inhibition by JMV-2764

Zelapar for Parkinson's disease now available

GSK profile GSK-189254 at ICAD meeting

Chemically programmed antibodies: a potential new class of antitumor agents

New dopamine D3 receptor antagonist shows antipsychotic activity lacking D2-related side effects

Positive in vitro safety profile of beta-secretase inhibitors from LG Life Sciences

New therapeutic strategies for cancer imparted in recent patents

Antiglaucoma agents revealed by French researchers

Agents for wound healing and pruritus described

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...